IGF1 and colorectal carcinoma: Only a detailed understanding of the multifaceted role of the various components of the insulin/IGF system and the validation of predictive biomarkers will allow the appropriate and successful use of anti IGF-1/2 or anti-IGF1R drugs, alone or in combination with other agents, for the treatment of CRC patients.